{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:57:18Z","timestamp":1781607438256,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metastatic castration-resistant prostate cancer (mCRPC) treatment has advanced with therapies such as androgen receptor pathway inhibitors (ARPIs), taxane chemotherapies like docetaxel, and novel agents like\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA. However, predicting patient responses and sequencing therapies remain critical unmet needs. This study investigated whether the PROSTest, a molecular assay analyzing prostate cancer-specific transcripts, could predict treatment response or prognosis in mCRPC patients receiving docetaxel, compared to changes in prostate-specific antigen (PSA) levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nineteen patients with mCRPC were treated with a median of 10 docetaxel cycles. PROSTest, which measures tumor-related signaling pathways, was analyzed via qPCR, while PSA levels were determined using standard clinical assays. PSA and PROSTest scores were measured at baseline and after one treatment cycle. PROSTest, which evaluates tumor-related signaling pathways, was analyzed via qPCR, and prostate-specific antigen (PSA) levels were measured using standard clinical assays. Responses were categorized per Prostate Cancer Working Group 3-criteria. Associations between biomarker changes, progression-free survival (PFS), and overall survival (OS) were evaluated using Kaplan-Meier survival analysis and hazard ratios (HRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline PSA and PROSTest scores did not predict response or survival. However, early changes in both biomarkers after one treatment cycle significantly correlated with PSA-PFS. PROSTest changes demonstrated a stronger association with PFS (HR: 0.04) compared to PSA (HR: 0.2). Early changes in PROSTest were also significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03, AUC\u2009=\u20090.81\u2009\u00b1\u20090.14) associated with OS in contrast to PSA changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pilot study suggests that PROSTest may offer superior predictive and prognostic value compared to PSA in mCRPC patients undergoing docetaxel therapy. Larger, multicenter studies are needed to confirm these findings and validate the assay\u2019s clinical integration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT06872619.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-14549-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:50:57Z","timestamp":1752137457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study"],"prefix":"10.1186","volume":"25","author":[{"given":"Kambiz","family":"Rahbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"14549_CR1","doi-asserted-by":"crossref","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87(2):157\u2013216.","DOI":"10.1016\/j.eururo.2024.09.017"},{"issue":"12","key":"14549_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10","key":"14549_CR3","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.21037\/tau-20-1341","volume":"10","author":"C Maurice Dror","year":"2021","unstructured":"Maurice Dror C, Chi KN, Khalaf DJ. Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer-a narrative review. Translational Androl Urol. 2021;10(10):3931\u201345.","journal-title":"Translational Androl Urol"},{"issue":"4","key":"14549_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2025.01.010","volume":"87","author":"AA Azad","year":"2025","unstructured":"Azad AA, Kostos L, Agarwal N, Attard G, Davis ID, Dorff T, Gillessen S, Parker C, Smith MR, Sweeney CJ, et al. Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. Eur Urol. 2025;87(4):455\u201367.","journal-title":"Eur Urol"},{"issue":"2","key":"14549_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242\u20135.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14549_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate Cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14549_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/annonc\/mdn062","volume":"19","author":"R Thuret","year":"2008","unstructured":"Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. The postchemotherapy PSA surge syndrome. Ann Oncol. 2008;19(7):1308\u201311.","journal-title":"Ann Oncol"},{"issue":"9","key":"14549_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/pros.23357","volume":"77","author":"V Conteduca","year":"2017","unstructured":"Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, et al. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. Prostate. 2017;77(9):1012\u20139.","journal-title":"Prostate"},{"issue":"3","key":"14549_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.12954\/PI.13024","volume":"1","author":"G Song","year":"2013","unstructured":"Song G, Lee C, You D, Jeong IG, Hong JH, Ahn H, Kim CS. Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. Prostate Int. 2013;1(3):125\u201332.","journal-title":"Prostate Int"},{"issue":"2","key":"14549_CR10","first-page":"633","volume":"32","author":"D Schallier","year":"2012","unstructured":"Schallier D, Decoster L, Braeckman J, Fontaine C, Degr\u00e8ve J. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. Anticancer Res. 2012;32(2):633\u201341.","journal-title":"Anticancer Res"},{"issue":"6","key":"14549_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.euo.2018.05.009","volume":"1","author":"N Delanoy","year":"2018","unstructured":"Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, et al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. Eur Urol Oncol. 2018;1(6):467\u201375.","journal-title":"Eur Urol Oncol"},{"key":"14549_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121908","author":"A Lapini","year":"2019","unstructured":"Lapini A, Caffo O, Pappagallo G, Iacovelli R, D\u2019Angelillo RM, Vavassori V, Ceccarelli R, Bracarda S, Jereczek-Fossa BA, Da Pozzo L, et al. Monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer: a multidisciplinary consensus document. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11121908.","journal-title":"Cancers"},{"issue":"9","key":"14549_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/pros.24704","volume":"84","author":"IM Modlin","year":"2024","unstructured":"Modlin IM, Kidd M, Drozdov IA, Boegemann M, Bodei L, Kunikowska J, Malczewska A, Bernemann C, Koduru SV, Rahbar K. Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood. Prostate. 2024;84(9):850\u201365.","journal-title":"Prostate"},{"key":"14549_CR14","doi-asserted-by":"crossref","unstructured":"Rahbar K, Kidd M, Prasad V, David Rosin R, Drozdov I, Halim A. Clinical sensitivity and specificity of the prostest in an American cohort. Prostate 2025;85(6):558\u201366.","DOI":"10.1002\/pros.24858"},{"issue":"6","key":"14549_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218592","volume":"14","author":"M Kidd","year":"2019","unstructured":"Kidd M, Drozdov IA, Matar S, Gurunlian N, Ferranti NJ, Malczewska A, Bennett P, Bodei L, Modlin IM. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS One. 2019;14(6): e0218592.","journal-title":"PLoS One"},{"key":"14549_CR16","volume-title":"Discovering statistics using IBM SPSS statistics","author":"A Field","year":"2017","unstructured":"Field A. Discovering statistics using IBM SPSS statistics. 5th ed. London: SAGE Publications LTD; 2017.","edition":"5"},{"issue":"2","key":"14549_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41391-023-00751-6","volume":"27","author":"ME Ahmed","year":"2024","unstructured":"Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, et al. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(2):334\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"14549_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","volume":"73","author":"V Cucchiara","year":"2018","unstructured":"Cucchiara V, Cooperberg MR, Dall\u2019Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic markers in prostate Cancer decision making. Eur Urol. 2018;73(4):572\u201382.","journal-title":"Eur Urol"},{"issue":"5","key":"14549_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582\u201391.","journal-title":"JAMA Oncol"},{"issue":"3","key":"14549_CR20","first-page":"123","volume":"18","author":"D Albala","year":"2016","unstructured":"Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D, Denes B, McCall M, Shindel AW, Dubeck F. Health economic impact and prospective clinical utility of oncotype DX\u00ae genomic prostate score. Rev Urol. 2016;18(3):123\u201332.","journal-title":"Rev Urol"},{"issue":"11","key":"14549_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","volume":"31","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428\u201334.","journal-title":"J Clin Oncol"},{"key":"14549_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114007","volume":"202","author":"UN Vaishampayan","year":"2024","unstructured":"Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, \u00c1rkosy PF, Cs\u00f6szi T, Wiechno P, Kopyltsov E, Orlov SV, et al. A global phase II randomized trial comparing oral taxane ModraDoc006\/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024;202: 114007.","journal-title":"Eur J Cancer"},{"issue":"4","key":"14549_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/0284186X.2023.2199940","volume":"62","author":"A Josefsson","year":"2023","unstructured":"Josefsson A, Jellvert \u00c5, Holmberg E, Brasso K, Meidahl Petersen P, Aaltomaa S, Luukkaa M, Verhagen P, de Wit R, Ahlgren G, et al. Effect of docetaxel added to bicalutamide in hormone-na\u00efve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). Acta Oncol. 2023;62(4):372\u201380.","journal-title":"Acta Oncol"},{"issue":"1","key":"14549_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euo.2024.04.010","volume":"8","author":"D Sentana-Lledo","year":"2025","unstructured":"Sentana-Lledo D, Chu X, Jarrard DF, Carducci MA, DiPaola RS, Wagner LI, Cella D, Sweeney CJ, Morgans AK. Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED). Eur Urol Oncol. 2025;8(1):29\u201337.","journal-title":"Eur Urol Oncol"},{"key":"14549_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175604","author":"A Sidhu","year":"2023","unstructured":"Sidhu A, Khan N, Phillips C, Briones J, Kapoor A, Zalewski P, Fleshner NE, Chow E, Emmenegger U. Prevalence and prognostic implications of PSA flares during Radium-223 treatment among men with metastatic castration resistant prostate cancer. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12175604.","journal-title":"J Clin Med"},{"key":"14549_CR26","doi-asserted-by":"publisher","first-page":"10251","DOI":"10.2147\/CMAR.S270392","volume":"12","author":"S Espa\u00f1a","year":"2020","unstructured":"Espa\u00f1a S, Ochoa de Olza M, Sala N, Piulats JM, Ferrandiz U, Etxaniz O, Heras L, Buisan O, Pardo JC, Suarez JF, et al. PSA kinetics as prognostic markers of overall survival in patients with metastatic Castration-Resistant prostate Cancer treated with abiraterone acetate. Cancer Manage Res. 2020;12:10251\u201360.","journal-title":"Cancer Manage Res"},{"issue":"10","key":"14549_CR27","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-22-3233","volume":"29","author":"S Gupta","year":"2023","unstructured":"Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, et al. PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate-resistant prostate cancer. Clin Cancer Res. 2023;29(10):1929\u201337.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14549-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:42:00Z","timestamp":1781606520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-14549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14549"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14549-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blood sampling and inclusion in the study was approved by the Ethics Committee of \u00c4rztekammer Westfalen-Lippe (2007-467-fS) and conducted in accordance with Good Clinical Practice principles. Informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1159"}}